317 related articles for article (PubMed ID: 9765749)
1. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.
Quirt I; Micucci S; Moran LA; Pater J; Browman G
Cancer Prev Control; 1997 Aug; 1(3):241-8. PubMed ID: 9765749
[TBL] [Abstract][Full Text] [Related]
2. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
4. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
5. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
6. Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Provincial Breast Disease Site Group.
Whelan TJ; Lada BM; Laukkanen E; Perera FE; Shelley WE; Levine MN
Cancer Prev Control; 1997 Aug; 1(3):228-40. PubMed ID: 9765748
[TBL] [Abstract][Full Text] [Related]
7. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
Lopez PG; Stewart DJ; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):18-27. PubMed ID: 9765723
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
10. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
Crawford J
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
[TBL] [Abstract][Full Text] [Related]
12. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
15. [Standards, Options, and Recommendations for using erythropoietin in cancerology].
Spaëth D; Marchal C; Blanc-Vincent MP
Bull Cancer; 1998 Apr; 85(4):337-46. PubMed ID: 9752298
[TBL] [Abstract][Full Text] [Related]
16. EPO in cancer anemia: benefits and potential risks.
Milano M; Schneider M
Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
[TBL] [Abstract][Full Text] [Related]
17. [Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology. FEDERATION OF THE FRENCH CANCER CENTRES (FNCLCC)].
Spaëth D; Marchal C; Bataillard A; Blanc-Vincent MP
Bull Cancer; 1999; 86(7-8):631-9. PubMed ID: 10477381
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
Borg S; Glenngård AH; Osterborg A; Persson U
Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoietin: a study of its use in oncohematology].
Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]